GlaxoSmithKline cell therapy lead leaves for partner; Ferring and Igenomix create Boston hub for maternal health

2020-06-04

合作抗体细胞疗法

→ GlaxoSmithKline is losing its cell therapy R&D chief to a partner. Immatics hired Cedrik Britten, who had been head of GSK’s oncology cell therapy research unit, as CMO. In February, GSK struck an up-to $600 million deal with Immatics ($50 million upfront) to use their bi-specific T-cell receptor platform. Immatics’ current CMO Carsten Reinhardt will become chief development officer. → Switzerland-based Ferring and Spain’s Igenomix have signed a maternal health and reproductive medicine research pact. The pact will see the two companies create a research hub in Boston in an effort to discover new targets and disease mechanisms for infertility and other pregnancy-related conditions. → The big players in MacroGenics’ pipeline are the HER2-targeting margetuximab and MGD013 and B7H3-targeted MGC018, but the Maryland biotech today published data supporting a third program. In Science Translational Medicine , the company showed gene expression signatures in tumor micro-environments that correlate to resistance to chemotherapy and susceptibility to their experimental antibody f lotetuzumab. The CD123 and CD3-targeted drug is heading for a pivotal study in acute myeloid leukemia.

机构